BETHESDA, Md., Feb. 26, 2015 \/PRNewswire-USNewswire\/ --The National Foundation for Cancer Research (NFCR) announced today that Frederick Alt, Ph.D., Professor of Genetics at Harvard Medical School, Director of the Program in Cellular and Molecular Medicine at Boston Children's Hospital, and Howard Hughes Medical Institute Investigator has been awarded the 2015 Szent-Gyrgyi Prize for Progress in Cancer Research. Dr. Alt's groundbreaking work in cancer genetics over four decades has helped to shape the very roots of modern cancer research. Today, that work continues to bear fruit, profoundly impacting the approaches that doctors use to diagnose and treat cancer. <\/p>\n
NFCR's selection committee was unanimous in its decision to recognize Dr. Alt, whose work has proved foundational to the modern understanding of cancer not only how the lethal disease forms, but also how it can become resistant to treatment. In particular, his seminal discoveries of gene amplification and his pioneering work on molecular mechanisms of DNA damage repair have helped to usher in the era of genetically-targeted therapy and personalized medicine. <\/p>\n
\"Dr. Alt has been a consistently outstanding scientist throughout his career, and this award recognizes his entire body of work,\" said Dr. James Allison, Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center, winner of the 2014 Szent-Gyrgyi Prize, and Chair of this year's Prize Selection Committee. \"The genetic processes he described are central to understanding the mechanisms that cause cancer, and have ultimately led to an entire class of targeted therapy and associated diagnostics that are providing benefit to countless cancer patients.\" <\/p>\n
Dr. Alt's discovery of gene amplification in chemotherapy-resistant cancer cellswhich revealed that cells can produce multiple copies of a genewas revolutionary, coming at a time when the human genome was widely believed to be stable and inflexible. This radical new concept suggested that cancer cells could change their genes, a process that would both allow them to develop more potent cancer-causing genes as well as evolve resistance to treatment. Dr. Alt proved the generality of his initial discoveries when he showed that the gene n-myc is commonly amplified in the childhood cancer neuroblastoma. Today, genomic instability is recognized as one of the hallmarks of cancer. <\/p>\n
Equally important is Dr. Alt's work on the critical DNA repair mechanism called \"non-homologous end joining\" (NHEJ). Dr. Alt not only made the initial experimental findings that led to the discovery of this pathway, but also carried out an ingenious series of experiments over many years in his lab in Boston, taking it apart piece by piece to understand how it works. This work linked NHEJ to protecting against a specific kind of DNA damage called \"translocations,\" which is a major component of many cancers, especially leukemia and lymphoma. <\/p>\n
Both amplified genes and translocated genes are key components of the Precision Medicine paradigm, which is at the heart of 21st century medicine. By identifying the source of genetic abnormalities that drive both cancer development and drug resistance, Dr. Alt's insights helped to revolutionize cancer diagnostics and treatment. His discoveries led to a wholly new approach to treating cancer identifying these genetic abnormalities then selecting new drugs that target each specifically. <\/p>\n
\"I am truly honored to be selected by the National Foundation for Cancer Research to receive this award, and I am humbled to stand with past winners of the Szent-Gyrgyi Prize,\" said Dr. Alt. \"Cancer is a complex and terrible disease, but with each new discovery we are making it less mysterious, more understandable, and ultimately less deadly. We are making progress.\" <\/p>\n
\"Dr. Alt's work has uncovered and explained some of the most foundational chemistry of life, and throughout his career he has always been focused on the implications for cancer. His vision and talent were instrumental in bringing cancer research into the modern era, and we are proud to present him with this award,\" said Sujuan Ba, Ph.D., Co-chair of the 2015 Szent-Gyrgyi Prize Selection Committee and President of NFCR. <\/p>\n
Dr. Alt will be honored at an award ceremony held April 29, 2015 at The National Press Club in Washington, D.C. Media and the public are invited and encouraged to attend. <\/p>\n
About the Szent-Gyrgyi Prize for Progress in Cancer Research <\/p>\n
<\/p>\n
Read the rest here: <\/p>\n
Frederick Alt of Harvard University and Boston Children's Hospital Awarded 2015 Szent-Gyorgyi Prize for Progress in ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" BETHESDA, Md., Feb. 26, 2015 \/PRNewswire-USNewswire\/ --The National Foundation for Cancer Research (NFCR) announced today that Frederick Alt, Ph.D., Professor of Genetics at Harvard Medical School, Director of the Program in Cellular and Molecular Medicine at Boston Children's Hospital, and Howard Hughes Medical Institute Investigator has been awarded the 2015 Szent-Gyrgyi Prize for Progress in Cancer Research Continue reading